HC Wainwright Issues Pessimistic Outlook for Savara Earnings

Savara Inc. (NASDAQ:SVRA) – Research analysts at HC Wainwright reduced their Q2 2026 earnings per share estimates for shares of Savara in a report issued on Thursday, May 14th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.15) per share for the quarter, down from their prior forecast of ($0.14). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.56) per share. HC Wainwright also issued estimates for Savara’s Q3 2026 earnings at ($0.15) EPS, Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.59) EPS, FY2027 earnings at ($0.34) EPS, FY2028 earnings at ($0.04) EPS, FY2029 earnings at $0.11 EPS and FY2030 earnings at $0.39 EPS.

A number of other research firms have also recently issued reports on SVRA. Oppenheimer started coverage on Savara in a research note on Friday, April 24th. They set an “outperform” rating and a $11.00 target price for the company. William Blair set a $10.00 target price on Savara in a research note on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Savara in a research note on Tuesday, April 21st. Finally, Wall Street Zen cut Savara from a “hold” rating to a “sell” rating in a research note on Saturday, March 14th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $9.13.

Savara Price Performance

NASDAQ SVRA opened at $4.91 on Tuesday. The business has a 50 day simple moving average of $5.34 and a 200 day simple moving average of $5.49. Savara has a 52-week low of $1.89 and a 52-week high of $7.01. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.47 and a current ratio of 13.47. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of -8.77 and a beta of 0.28.

Savara (NASDAQ:SVRA) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.15) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01).

Hedge Funds Weigh In On Savara

Hedge funds have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Savara by 48.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock worth $60,000 after acquiring an additional 3,205 shares in the last quarter. Principal Financial Group Inc. bought a new position in shares of Savara during the 1st quarter worth approximately $57,000. Russell Investments Group Ltd. grew its stake in shares of Savara by 930.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 10,480 shares of the company’s stock worth $37,000 after acquiring an additional 9,463 shares in the last quarter. Xponance LLC bought a new position in shares of Savara during the 4th quarter worth approximately $66,000. Finally, CIBC Bancorp USA Inc. bought a new position in shares of Savara during the 3rd quarter worth approximately $44,000. 87.93% of the stock is owned by institutional investors.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.